OncoMatch/Clinical Trials/NCT05024097
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Is NCT05024097 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Etrumadenant (AB928) and FOLFOX regimen for rectal cancer.
Treatment: Etrumadenant (AB928) · FOLFOX regimen · Zimberelimab (AB122) — Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CT3N0, CT1-3N1, CN2 (clinical TNM)
cT3N0 or cT1-3N1 or cT4 or cN2
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic radiation therapy
No prior pelvic radiation therapy
Cannot have received: chemotherapy
No prior chemotherapy or surgery for rectal cancer
Cannot have received: surgery
No prior chemotherapy or surgery for rectal cancer
Cannot have received: agent targeting the adenosine pathway
Prior treatment with an agent targeting the adenosine pathway
Cannot have received: allogenic stem cell or solid organ transplantation
Patients with prior allogenic stem cell or solid organ transplantation
Lab requirements
Blood counts
Hgb >8.0 gm/dL, PLT > 150,000/mm3
Kidney function
Serum creatinine level ≤ 1.5x the upper limit of normal
Liver function
total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal
Cardiac function
QTc < 480 msec using Fredericia's QT correction formula
Hgb >8.0 gm/dL, PLT > 150,000/mm3, total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal; Serum creatinine level ≤1.5x the upper limit of normal; QTc ≥480 msec using Fredericia's QT correction formula [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Weill Cornell Medical College · New York, New York
- Brooklyn Methodist Hospital - NewYork Presbyterian · New York, New York
- New York Presbyterian Hospital - Queens · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify